Drug updated on 10/28/2024
| Dosage Form | Tablets (oral; 25 mg, 50 mg, 100 mg, 200 mg and 300 mg) |
| Drug Class | Kinase Inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for Gastrointestinal Stromal Tumor (GIST): the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
- Indicated for Advanced Systemic Mastocytosis (AdvSM): the treatment of adult patients with AdvSM
- AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL)
- Indicated for Indolent Systemic Mastocytosis (ISM): the treatment of adult patients with ISM.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- The adjusted hazard ratio (95% CI (HR)) for overall survival (OS) when comparing avapritinib to midostaurin is 0.44 (95% CI: 0.25-0.76), indicating avapritinib may improve survival in patients with advanced systemic mastocytosis.
- The adjusted odds ratio (ORR) for overall response rate (ORR) for avapritinib versus midostaurin is 4.06 (95% CI: 3.09-5.33), suggesting a higher likelihood of treatment response with avapritinib.
- The adjusted odds ratio for complete remission (CR) for avapritinib compared to midostaurin is 9.56 (95% CI: 0.97-93.81), showing potential improvement in achieving complete remission with avapritinib, though the wide confidence interval indicates variability in the estimate.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ayvakit (avapritinib) Prescribing Information. | 2023 | Blueprint Medicines Corporation., Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis | 2022 | Future Oncology (London, England) |